These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Generalized pustular psoriasis in pregnancy, successfully treated with certolizumab pegol. Mizutani Y; Mizutani YH; Matsuyama K; Kawamura M; Fujii A; Shu E; Ohnishi H; Seishima M J Dermatol; 2020 Jul; 47(7):e262-e263. PubMed ID: 32363682 [No Abstract] [Full Text] [Related]
50. Psoriasiform skin eruption in a patient receiving certolizumab-pegol for ankylosing spondylitis: Report of a case and review of the literature. Babuna Kobaner G; Polat Ekinci A; Yilmaz Z; Copur S Dermatol Ther; 2018 Sep; 31(5):e12693. PubMed ID: 30225952 [TBL] [Abstract][Full Text] [Related]
51. Certolizumab pegol - Tumor necrosis factor inhibitor for refractory uveitis. Sharon Y; Chu DS Am J Ophthalmol Case Rep; 2020 Jun; 18():100633. PubMed ID: 32190782 [TBL] [Abstract][Full Text] [Related]
52. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. Esposito M; Carubbi F; Giunta A; Alunno A; Giacomelli R; Fargnoli MC Expert Rev Clin Immunol; 2020 Feb; 16(2):119-128. PubMed ID: 31917928 [No Abstract] [Full Text] [Related]
53. Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results. Okubo Y; Umezawa Y; Sakurai S; Hoshii N; Nakagawa H Dermatol Ther (Heidelb); 2022 Jun; 12(6):1397-1415. PubMed ID: 35622315 [TBL] [Abstract][Full Text] [Related]
54. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options. Menter A; Van Voorhees AS; Hsu S Dermatol Ther (Heidelb); 2021 Dec; 11(6):1917-1929. PubMed ID: 34626330 [TBL] [Abstract][Full Text] [Related]
55. Successful management of infliximab-induced generalized pustular psoriasis without therapy discontinuation in a patient with psoriatic arthritis. Zheng J; Gao Y; Ding Y Dermatol Ther; 2019 Nov; 32(6):e13132. PubMed ID: 31631466 [TBL] [Abstract][Full Text] [Related]
56. Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis. Carubbi F; Fidanza R; Palmieri M; Ventura A; Tambone S; Cipriani P; Giacomelli R; Fargnoli MC J Dermatolog Treat; 2020 Nov; 31(7):692-697. PubMed ID: 30963798 [No Abstract] [Full Text] [Related]
57. Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis. Lee A; Scott LJ BioDrugs; 2020 Apr; 34(2):235-244. PubMed ID: 32207094 [TBL] [Abstract][Full Text] [Related]
58. Successful Certolizumab Pegol Treatment of Chronic Anterior Uveitis Associated with Psoriasis Vulgaris. Yamaguchi K; Hayashi T; Takahashi G; Momose M; Asahina A; Nakano T Case Rep Ophthalmol; 2018; 9(3):499-503. PubMed ID: 30687070 [TBL] [Abstract][Full Text] [Related]
59. Certolizumab pegol, a pegylated anti-TNF-α antagonist, caused de novo-onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis. Koizumi H; Tokuriki A; Oyama N; Ido H; Sugiura K; Akiyama M; Hasegawa M J Dermatol; 2017 Jun; 44(6):723-724. PubMed ID: 27599405 [No Abstract] [Full Text] [Related]
60. Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab. Herrero-Moyano M; Capusan TM; Martínez-Mera C; Llamas-Velasco M; Daudén E JAAD Case Rep; 2018 Sep; 4(8):842-844. PubMed ID: 30246137 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]